GINWA(SH:600080) Xi Niu Cai Jing·2025-12-21 05:53Core Viewpoint - Jin Hua Enterprise (Group) Co., Ltd. faced regulatory penalties due to Chairman Xing Yajiang's failure to timely disclose personal legal matters, resulting in a warning and a fine of 3.5 million yuan from the Shaanxi Securities Regulatory Bureau [2][4]. Group 1: Regulatory Issues - Xing Yajiang was placed under residential surveillance by the Xi'an Public Security Bureau on April 23, 2024, but was released on July 26, 2024, due to insufficient evidence [4]. - The company disclosed the legal matter only on August 24, 2024, which was deemed a violation of information disclosure regulations by the Shaanxi Securities Regulatory Bureau [4]. - Xing's defense during the hearing, claiming uncertainty about his legal status and arguing that the punishment was excessive, was rejected due to lack of supporting evidence [4]. Group 2: Previous Violations - Since the beginning of 2024, Xing Yajiang has been involved in multiple regulatory violations, including inaccurate disclosures regarding Jin Hua's 2023 performance forecast, which led to criticism from the Shanghai Stock Exchange and a warning letter from the Shaanxi Securities Regulatory Bureau [5]. Group 3: Company Overview - Jin Hua's main business includes the research, production, and sales of pharmaceuticals, with a product line that encompasses chemical drugs, traditional Chinese medicine, raw materials, and health products [5]. - The company offers over a hundred varieties of dosage forms, including tablets, capsules, and granules, categorized into series such as orthopedic, immunological, pediatric, and general medicines [5].